ArticleCancer2018
Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06056791 (An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy), which is not on this map. Cited by 125 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Who cites it
125 citing papers in PubMed, 3 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk.Prostate cancer and prostatic diseases · 2021Pooled it
- Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.The oncologist · 2021Pooled it
- Can Lycopene Impact the Androgen Axis in Prostate Cancer?: A Systematic Review of Cell Culture and Animal Studies.Nutrients · 2019Pooled it
- Focal therapy using a novel cooled laser device for prostate cancer: early trial results.BJU international · 2026Trial
- Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.The oncologist · 2022Trial
- Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?PloS one · 2019Trial
- Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy.Prostate cancer and prostatic diseases · 2026Article
- Dynamic Shifts in ER-Plasma Membrane Junctions Signaling Define Pro-Metastatic N-Glycosylation and Predict Prostate Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Real-World Economic Outcomes of Patients with Localized Prostate Cancer Treated with External Beam Radiation Therapy or Radical Prostatectomy.Journal of health economics and outcomes research · 2026Article
- Preliminary Estimates of New Invasive Cancers Diagnosed in 2023 in the United States.Journal of registry management · 2026Article
- Sustained PSA screening is associated with downstaging and improved survival in prostate cancer: a 12-year Korean cohort study.BMC cancer · 2025Article
- Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study.Prostate cancer and prostatic diseases · 2025Article
- Prostate Cancer Mortality Trend in Montenegro 1990-2018.Iranian journal of public health · 2025Article
- Trends in Prostate Cancer Incidence and Survival by Gleason Score from 2000 to 2020: A Population-Based Study in Northeastern Italy.Current oncology (Toronto, Ont.) · 2025Article
- Global trends in testicular and prostate cancer among adolescents and young adult males aged 15-49 years, 1990-2021: insights from the GBD study.Scientific reports · 2025Article
- Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.BJU international · 2025Article
- A retrospective analysis of tissue, liquid, and germline testing in Hispanic and non-Hispanic men with advanced hormone-sensitive prostate cancer.Urologic oncology · 2025Article
- Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups.European journal of histochemistry : EJH · 2025Article
- Small Area Estimation of PSA Testing in US States and Counties.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Chronological Trends of PSA Levels at Diagnosis in Population-based Prostate Cancer Data 2004-2021, a Time Period of Drastic Changes in Screening Guidelines: Potential Implications in Prostate Cancer Diagnosis.Journal of registry management · 2025Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundTemporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national-level trends and their relations with prostate-specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage-specific, delay-adjusted rates.
methodsJoinpoint regression was used to examine changes in delay-adjusted prostate cancer incidence rates from population-based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points.
resultsFor all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant-stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015.
conclusionsAfter a decline in PSA test usage, there has been an increased burden of late-stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801-2814. © 2018 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.